Trupanion Inc Dossier - Source-backed chat

Trupanion Inc

TRUPNASDAQ

SectorFinancials

IndustryInsurance - Property & Casualty

Beta (adjusted)1.29

Intrinsic Value $40.81median of 5 methods · middle span $14-$49based on filings through 30 Jun 2026

Market Price $23.36Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 75% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+75%)

Data confidence Sign in to view data confidence

Market Cap $1B

Enterprise Value $976.5M

Shares Outstanding 43.8M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Trupanion is successfully transitioning from a growth-at-all-costs model to a highly disciplined, profitable enterprise. Having achieved its first full year of GAAP net income in 2025, the company's Q1 2026 results demonstrate strong operating leverage, record subscription margins, and robust free cash flow generation. Operating in a highly underpenetrated North American market (less than 4% penetration), Trupanion's proprietary direct-payment technology and deep veterinary relationships provide a powerful competitive moat. While veterinary inflation and rising pet acquisition costs (PAC) remain key risks, the company's pricing power and disciplined capital allocation support a compelling long-term investment case.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$28.00

Mean target$37.25

High · most bullish analyst$45.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$28.00

In the bear case, persistent high veterinary inflation triggers severe regulatory delays in rate approvals, squeezing underwriting margins. Concurrently, customer acquisition costs (PAC) escalate inefficiently, and a macroeconomic downturn prompts price-sensitive pet owners to cancel subscriptions, driving monthly retention below 98% and stalling top-line growth.

Base CaseCentral scenario

$37.25

Matches the consensus mean

The base case assumes Trupanion delivers on its 2026 guidance, achieving subscription revenue growth of approximately 14% and adjusted operating income growth of 19% at the midpoint. Retention remains stable around 98.3%, and pricing increases successfully offset veterinary inflation. The company continues to expand its product flexibility and launches its new digital-first product to capture younger, price-sensitive demographics, driving steady GAAP profitability.

Bull CaseUpside scenario

$45.00

Under the bull case, pet insurance penetration in North America accelerates rapidly toward European levels, driven by the humanization of pets and rising veterinary costs. Trupanion's direct-payment software becomes the industry standard, driving high conversion and retention. Pricing adjustments seamlessly outpace veterinary inflation, leading to subscription adjusted operating margins exceeding 15% and rapid expansion of free cash flow.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary direct-payment technology that pays veterinarians directly in seconds, creating a unique competitive moat and superior customer experience.
Highly underpenetrated addressable market in North America (less than 4% penetration) compared to mature European markets like the UK (28%) and Sweden (67%).
Strong recurring subscription business model with high customer loyalty, evidenced by a monthly retention rate consistently above 98.3%.
Demonstrated pivot to GAAP profitability and strong free cash flow generation, reducing reliance on external capital markets.

Key Investment Risks

Persistent veterinary care inflation that outpaces the company's ability to implement timely, regulatory-approved premium rate increases.
Rising pet acquisition costs (PAC) that reduce the internal rate of return (IRR) on new pet cohorts below the target threshold.
Intensifying competition from well-capitalized traditional insurers and agile insurtech startups offering lower-priced or bundled products.
Regulatory and compliance risks across multiple jurisdictions in the U.S. and Canada, which can restrict pricing flexibility and capital mobility.

Thesis Invalidation Triggers

A sustained drop in the monthly average retention rate below 98.0%, indicating deteriorating customer satisfaction or severe economic pressure on consumers.
A significant decline in the estimated internal rate of return (IRR) on new pet acquisitions below the historical 30% threshold.
Prolonged regulatory delays or denials of state-level rate filings that prevent the company from matching premium increases to veterinary inflation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.